Héma-Québec, the organization in Quebec that manages blood and biological products, has awarded a two-year tender for TAKHZYRO® (lanadelumab injection), as the sole option for prophylaxis subcutaneous

HAE International is offering free, online advocacy courses. This extremely comprehensive program is designed to support people with HAE in everyday life. The courses are delivered in small manageable chunks and can

Please join us on Saturday November 20th from 1:00-3:00pm ET for our next Update! Details can also be found on our Upcoming Events page.

We hope you can join us for our 2021 AGM. Please check your inbox for the invitation and links to register. Please check your spam box if you

Please mark your calendars! HAE Canada is hosting a Virtual Patient Information Update on November 20th at 1:00pm ET. Speakers, topics and other important details will be shared

Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova

Who is Heather Dow? Heather has been supporting HAE Canada in many ways over the years, from providing technical support for our virtual Patient Information Updates and organizing

Congratulations to the Canadian HAE Community! Canadians logged the most steps to win the 2021 Global Walk for a third time. Thank you very much to all who

Happy HAE Day and Happy 10th Anniversary! We hope everyone celebrated HAE Day 🙂 by doing something extra fun. Did you go for a hike? Did you plant

HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab (TAKHZYRO), a subcutaneous preventative HAE treatment, to their provincial drug formulary. Please click

We are over the moon that our members are telling us that they are excited about having access to HAEGARDA, a subcutaneous C1 esterase inhibitor (C1-INH) prophylaxis therapy

We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was

We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood

We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now

Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more,

Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how

We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its

Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro)

We wanted to let our members know that starting February 1st, 2021, CSL Behring patient support programs (Hizentra™ CARE Program, and Berinert® Assistance Program) will be streamlined into

Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss HAE patients and the COVID vaccine. We encourage everyone to please watch this

We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug

Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed

We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab